Renaissance Technologies
NRXP icon

Renaissance Technologies’s NRX Pharmaceuticals NRXP Stock Holding History

Renaissance Technologies’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-128,175
Closed -$423K – 3587
2025
Q3 		$423K Buy
+128,175
New +$367K ﹤0.01% 2864
2024
Q2 		– Sell
-18,878
Closed -$89K – 3820
2024
Q1 		$89K Sell
18,878
-1,170
-6% -$5.39K ﹤0.01% 3395
2023
Q4 		$92K Buy
20,048
+3,670
+22% +$12.1K ﹤0.01% 3320
2023
Q3 		$43K Buy
16,378
+13,028
+389% +$43.3K ﹤0.01% 3428
2023
Q2 		$16K Buy
3,350
+820
+32% +$4.93K ﹤0.01% 3797
2023
Q1 		$17K Buy
2,530
+770
+44% +$7.8K ﹤0.01% 3844
2022
Q4 		$20K Buy
1,760
+315
+22% +$3.17K ﹤0.01% 3967
2022
Q3 		$11K Sell
1,445
-1,845
-56% -$12.4K ﹤0.01% 3943
2022
Q2 		$20K Sell
3,290
-10,610
-76% -$139K ﹤0.01% 4119
2022
Q1 		$341K Buy
+13,900
New +$452K ﹤0.01% 3411

Other funds holding NRXP

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFG
Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $5.64B AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies's NRXP Position: Q4 2025 in Review

Renaissance Technologies sold out of NRX Pharmaceuticals (NRXP) in Q4 2025, closing a stake of 128,175 shares — an estimated $423K sold.

Renaissance Technologies first reported a position in NRXP in Q1 2022 and held it in 10 quarters. The position peaked at $423K in Q3 2025. 28 funds tracked by Wall St. Rank hold NRXP as of Q4 2025.

  • Renaissance Technologies reported no remaining NRX Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Renaissance Technologies sold 128,175 NRX Pharmaceuticals shares in Q4 2025, an estimated $423K.
  • Renaissance Technologies first reported a position in NRX Pharmaceuticals in Q1 2022 and held it in 10 quarters.
  • Renaissance Technologies's NRX Pharmaceuticals position peaked at $423K in Q3 2025.
  • 28 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.